Ligand Pharmaceuticals Incorporated (LGND)
USD 99.8
(-3.21%)
USD 99.8
(-3.21%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 130.7 Million USD | -20.87% |
| 2022 | 165.18 Million USD | -65.57% |
| 2021 | 479.75 Million USD | -26.5% |
| 2020 | 652.76 Million USD | -7.02% |
| 2019 | 702.07 Million USD | 0.31% |
| 2018 | 699.88 Million USD | 177.32% |
| 2017 | 252.37 Million USD | 9.38% |
| 2016 | 230.73 Million USD | 0.52% |
| 2015 | 229.53 Million USD | -1.75% |
| 2014 | 233.62 Million USD | 323.99% |
| 2013 | 55.1 Million USD | -29.15% |
| 2012 | 77.77 Million USD | -31.6% |
| 2011 | 113.7 Million USD | 37.74% |
| 2010 | 82.55 Million USD | -24.92% |
| 2009 | 109.95 Million USD | -39.52% |
| 2008 | 181.81 Million USD | 26.12% |
| 2007 | 144.16 Million USD | -51.74% |
| 2006 | 298.7 Million USD | -29.72% |
| 2005 | 425.03 Million USD | 4.23% |
| 2004 | 407.78 Million USD | 76.89% |
| 2003 | 230.52 Million USD | 17.26% |
| 2002 | 196.59 Million USD | 12.12% |
| 2001 | 175.34 Million USD | 4.04% |
| 2000 | 168.54 Million USD | 5.21% |
| 1999 | 160.2 Million USD | -4.3% |
| 1998 | 167.4 Million USD | 129.0% |
| 1997 | 73.1 Million USD | 8.14% |
| 1996 | 67.6 Million USD | 3.21% |
| 1995 | 65.5 Million USD | 221.08% |
| 1994 | 20.4 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 107.34 Million USD | -17.87% |
| 2024 Q2 | 91.2 Million USD | -15.04% |
| 2023 Q1 | 164.75 Million USD | -0.26% |
| 2023 Q3 | 103.8 Million USD | 11.37% |
| 2023 Q4 | 130.7 Million USD | 25.91% |
| 2023 FY | 130.7 Million USD | -20.87% |
| 2023 Q2 | 93.21 Million USD | -43.42% |
| 2022 FY | 165.18 Million USD | -65.57% |
| 2022 Q2 | 273.92 Million USD | -12.2% |
| 2022 Q1 | 311.99 Million USD | -34.97% |
| 2022 Q4 | 165.18 Million USD | -29.5% |
| 2022 Q3 | 234.3 Million USD | -14.46% |
| 2021 FY | 479.75 Million USD | -26.5% |
| 2021 Q1 | 549.28 Million USD | -15.85% |
| 2021 Q2 | 469.76 Million USD | -14.48% |
| 2021 Q3 | 461.59 Million USD | -1.74% |
| 2021 Q4 | 479.75 Million USD | 3.94% |
| 2020 Q4 | 652.76 Million USD | 18.76% |
| 2020 Q3 | 549.62 Million USD | 0.31% |
| 2020 Q2 | 547.93 Million USD | 4.56% |
| 2020 Q1 | 524.02 Million USD | -25.36% |
| 2020 FY | 652.76 Million USD | -7.02% |
| 2019 FY | 702.07 Million USD | 0.31% |
| 2019 Q2 | 760.38 Million USD | -8.83% |
| 2019 Q3 | 696.89 Million USD | -8.35% |
| 2019 Q4 | 702.07 Million USD | 0.74% |
| 2019 Q1 | 834.01 Million USD | 19.16% |
| 2018 Q3 | 1.4 Billion USD | 13.55% |
| 2018 FY | 699.88 Million USD | 177.32% |
| 2018 Q4 | 699.88 Million USD | -50.23% |
| 2018 Q2 | 1.23 Billion USD | 380.98% |
| 2018 Q1 | 257.49 Million USD | 2.03% |
| 2017 Q2 | 230.61 Million USD | -0.14% |
| 2017 Q1 | 230.94 Million USD | 0.09% |
| 2017 FY | 252.37 Million USD | 9.38% |
| 2017 Q4 | 252.37 Million USD | 6.23% |
| 2017 Q3 | 237.57 Million USD | 3.02% |
| 2016 Q3 | 230.47 Million USD | 2.49% |
| 2016 Q1 | 221.36 Million USD | -3.56% |
| 2016 Q4 | 230.73 Million USD | 0.11% |
| 2016 FY | 230.73 Million USD | 0.52% |
| 2016 Q2 | 224.88 Million USD | 1.59% |
| 2015 Q1 | 230.82 Million USD | -1.2% |
| 2015 Q3 | 229.51 Million USD | -2.63% |
| 2015 FY | 229.53 Million USD | -1.75% |
| 2015 Q2 | 235.7 Million USD | 2.11% |
| 2015 Q4 | 229.53 Million USD | 0.01% |
| 2014 Q2 | 36.76 Million USD | -9.16% |
| 2014 Q3 | 229.5 Million USD | 524.3% |
| 2014 Q4 | 233.62 Million USD | 1.8% |
| 2014 FY | 233.62 Million USD | 323.99% |
| 2014 Q1 | 40.47 Million USD | -26.55% |
| 2013 Q2 | 60.3 Million USD | -11.01% |
| 2013 Q3 | 56.86 Million USD | -5.71% |
| 2013 Q1 | 67.76 Million USD | -12.87% |
| 2013 Q4 | 55.1 Million USD | -3.1% |
| 2013 FY | 55.1 Million USD | -29.15% |
| 2012 Q2 | 86.14 Million USD | -6.93% |
| 2012 Q3 | 76.27 Million USD | -11.46% |
| 2012 Q4 | 77.77 Million USD | 1.97% |
| 2012 FY | 77.77 Million USD | -31.6% |
| 2012 Q1 | 92.55 Million USD | -18.6% |
| 2011 FY | 113.7 Million USD | 37.74% |
| 2011 Q2 | 122.1 Million USD | -5.45% |
| 2011 Q1 | 129.14 Million USD | 60.61% |
| 2011 Q4 | 113.7 Million USD | -5.32% |
| 2011 Q3 | 120.09 Million USD | -1.65% |
| 2010 Q4 | 80.4 Million USD | -34.1% |
| 2010 Q3 | 122 Million USD | -2.35% |
| 2010 Q2 | 124.94 Million USD | -4.97% |
| 2010 Q1 | 131.47 Million USD | -4.77% |
| 2010 FY | 82.55 Million USD | -24.92% |
| 2009 Q4 | 138.06 Million USD | 9.07% |
| 2009 Q1 | 154.28 Million USD | -15.14% |
| 2009 Q2 | 141.43 Million USD | -8.33% |
| 2009 Q3 | 126.58 Million USD | -10.5% |
| 2009 FY | 109.95 Million USD | -39.52% |
| 2008 FY | 181.81 Million USD | 26.12% |
| 2008 Q1 | 141.73 Million USD | -1.69% |
| 2008 Q2 | 141 Million USD | -0.51% |
| 2008 Q3 | 145.23 Million USD | 3.0% |
| 2008 Q4 | 181.81 Million USD | 25.18% |
| 2007 FY | 144.16 Million USD | -51.74% |
| 2007 Q1 | 455.06 Million USD | 52.35% |
| 2007 Q2 | 194.24 Million USD | -57.31% |
| 2007 Q3 | 185.23 Million USD | -4.64% |
| 2007 Q4 | 144.16 Million USD | -22.17% |
| 2006 Q3 | 483.05 Million USD | -7.89% |
| 2006 Q4 | 298.7 Million USD | -38.16% |
| 2006 Q1 | 513.04 Million USD | 20.71% |
| 2006 Q2 | 524.43 Million USD | 2.22% |
| 2006 FY | 298.7 Million USD | -29.72% |
| 2005 Q1 | 407.2 Million USD | -0.14% |
| 2005 FY | 425.03 Million USD | 4.23% |
| 2005 Q2 | 404.11 Million USD | -0.76% |
| 2005 Q3 | 414.46 Million USD | 2.56% |
| 2005 Q4 | 425.03 Million USD | 2.55% |
| 2004 FY | 407.78 Million USD | 76.89% |
| 2004 Q4 | 407.78 Million USD | 64.63% |
| 2004 Q3 | 247.7 Million USD | 4.37% |
| 2004 Q2 | 237.31 Million USD | 1.5% |
| 2004 Q1 | 233.81 Million USD | 1.43% |
| 2003 Q1 | 203.15 Million USD | 3.34% |
| 2003 Q3 | 210.2 Million USD | 5.17% |
| 2003 Q2 | 199.87 Million USD | -1.61% |
| 2003 FY | 230.52 Million USD | 17.26% |
| 2003 Q4 | 230.52 Million USD | 9.67% |
| 2002 Q1 | 87.88 Million USD | -49.88% |
| 2002 FY | 196.59 Million USD | 12.12% |
| 2002 Q3 | 37.36 Million USD | -8.08% |
| 2002 Q4 | 196.59 Million USD | 426.2% |
| 2002 Q2 | 40.64 Million USD | -53.75% |
| 2001 FY | 175.34 Million USD | 4.04% |
| 2001 Q2 | 170.32 Million USD | 3.58% |
| 2001 Q3 | 169.13 Million USD | -0.7% |
| 2001 Q4 | 175.34 Million USD | 3.67% |
| 2001 Q1 | 164.44 Million USD | -2.43% |
| 2000 FY | 168.54 Million USD | 5.21% |
| 2000 Q3 | 145.35 Million USD | -0.31% |
| 2000 Q1 | 142.2 Million USD | -11.24% |
| 2000 Q2 | 145.8 Million USD | 2.53% |
| 2000 Q4 | 168.54 Million USD | 15.96% |
| 1999 Q4 | 160.2 Million USD | -9.34% |
| 1999 Q2 | 153.6 Million USD | 1.65% |
| 1999 Q1 | 151.1 Million USD | -9.74% |
| 1999 FY | 160.2 Million USD | -4.3% |
| 1999 Q3 | 176.7 Million USD | 15.04% |
| 1998 Q3 | 118.4 Million USD | 72.59% |
| 1998 Q1 | 66.7 Million USD | -8.76% |
| 1998 FY | 167.4 Million USD | 129.0% |
| 1998 Q4 | 167.4 Million USD | 41.39% |
| 1998 Q2 | 68.6 Million USD | 2.85% |
| 1997 Q3 | 61.8 Million USD | -4.48% |
| 1997 FY | 73.1 Million USD | 8.14% |
| 1997 Q4 | 73.1 Million USD | 18.28% |
| 1997 Q2 | 64.7 Million USD | 1.41% |
| 1997 Q1 | 63.8 Million USD | -5.62% |
| 1996 Q2 | 64 Million USD | 0.95% |
| 1996 Q4 | 67.6 Million USD | 14.38% |
| 1996 Q1 | 63.4 Million USD | -3.21% |
| 1996 Q3 | 59.1 Million USD | -7.66% |
| 1996 FY | 67.6 Million USD | 3.21% |
| 1995 FY | 65.5 Million USD | 221.08% |
| 1995 Q3 | 60.5 Million USD | 0.0% |
| 1995 Q1 | 19.1 Million USD | -6.37% |
| 1995 Q4 | 65.5 Million USD | 8.26% |
| 1994 Q4 | 20.4 Million USD | 5.15% |
| 1994 Q2 | 7.5 Million USD | 2.74% |
| 1994 Q3 | 19.4 Million USD | 158.67% |
| 1994 FY | 20.4 Million USD | 0.0% |
| 1994 Q1 | 7.3 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | 61.073% |
| Alkermes plc | 933.53 Million USD | 85.999% |
| Agenus Inc. | 462.29 Million USD | 71.726% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 96.773% |
| Aptorum Group Limited | 5.25 Million USD | -2386.466% |
| Ardelyx, Inc. | 130.76 Million USD | 0.043% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 72.678% |
| Bicycle Therapeutics plc | 224.41 Million USD | 41.756% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -0.382% |
| ChromaDex Corporation | 26.5 Million USD | -393.085% |
| Chimerix, Inc. | 19.74 Million USD | -561.975% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -271.568% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -80.119% |
| CRISPR Therapeutics AG | 346.76 Million USD | 62.307% |
| Precision BioSciences, Inc. | 140.92 Million USD | 7.247% |
| Dyadic International, Inc. | 2.34 Million USD | -5484.216% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -703.708% |
| Fortress Biotech, Inc. | 165.93 Million USD | 21.232% |
| Lantern Pharma Inc. | 2.73 Million USD | -4670.882% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -82.858% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -3604.086% |
| Incyte Corporation | 1.59 Billion USD | 91.791% |
| IO Biotech, Inc. | 17.55 Million USD | -644.515% |
| Jaguar Health, Inc. | 45.86 Million USD | -184.976% |
| Novavax, Inc. | 2.57 Billion USD | 94.919% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -262.491% |
| Opthea Limited | 264.6 Million USD | 50.602% |
| ContextLogic Inc. | 206 Million USD | 36.55% |
| MiMedx Group, Inc. | 96.33 Million USD | -35.687% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -172.182% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -3603.916% |
| NextCure, Inc. | 14.99 Million USD | -771.554% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -3133.721% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -1857.571% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -179.653% |
| Vaxcyte, Inc. | 167.44 Million USD | 21.942% |
| PDS Biotechnology Corporation | 33.25 Million USD | -292.996% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | 44.431% |
| Pharming Group N.V. | 244.07 Million USD | 46.448% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -996.351% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -2.282% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -1878.227% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -1878.227% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -58.561% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -1867.59% |
| Acelyrin, Inc. | 86.35 Million USD | -51.364% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -9960.258% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -809.013% |
| Summit Therapeutics Inc. | 125.25 Million USD | -4.351% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -1278.911% |
| Senti Biosciences, Inc. | 52.57 Million USD | -148.629% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -90.045% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | 13.732% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -6582.362% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -9686.652% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | 42.377% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -1295.399% |
| Wave Life Sciences Ltd. | 227.44 Million USD | 42.532% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 73.568% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -1097.609% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -375.108% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -979.804% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 73.139% |
| Immix Biopharma, Inc. | 3.72 Million USD | -3411.946% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -245.676% |
| MEI Pharma, Inc. | 8.35 Million USD | -1464.417% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -350.481% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 62.395% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | 10.394% |
| Fortress Biotech, Inc. | 165.93 Million USD | 21.232% |
| Precigen, Inc. | 41.64 Million USD | -213.868% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -161.78% |
| AlloVir, Inc. | 45.01 Million USD | -190.363% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -0.284% |
| Fate Therapeutics, Inc. | 137.8 Million USD | 5.147% |
| ImmuCell Corporation | 18.81 Million USD | -594.695% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -363.073% |
| Onconetix, Inc. | 23.18 Million USD | -463.857% |
| PureTech Health plc | 125.58 Million USD | -4.08% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -1360.413% |
| Elevation Oncology, Inc. | 34.28 Million USD | -281.27% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -5245.89% |
| Seer, Inc. | 39.36 Million USD | -232.039% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -111.384% |
| Innoviva, Inc. | 568.55 Million USD | 77.011% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -380.046% |
| ESSA Pharma Inc. | 3.49 Million USD | -3639.752% |
| GlycoMimetics, Inc. | 6.9 Million USD | -1793.735% |
| GT Biopharma, Inc. | 6.63 Million USD | -1870.556% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | 50.563% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 51.997% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -55.555% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -1237.293% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -381.089% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -3951.959% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -77.189% |
| Aptose Biosciences Inc. | 15.8 Million USD | -726.804% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -1083.974% |
| Soligenix, Inc. | 7.27 Million USD | -1696.684% |
| Century Therapeutics, Inc. | 175.94 Million USD | 25.71% |
| Kura Oncology, Inc. | 51.66 Million USD | -153.004% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -7.771% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -3062.521% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -1876.26% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | 48.255% |
| Autolus Therapeutics plc | 263.9 Million USD | 50.472% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -1146.966% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -47.092% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -178.699% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 62.957% |
| GRI Bio, Inc. | 2.69 Million USD | -4746.385% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -16044.938% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -320.401% |
| IGM Biosciences, Inc. | 220.17 Million USD | 40.635% |
| INmune Bio, Inc. | 18.86 Million USD | -592.965% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 49.038% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -390.609% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -4708.222% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -3884.646% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -123.603% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -35.928% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 50.627% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 84.119% |
| Verastem, Inc. | 71.18 Million USD | -83.616% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -165.794% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -238.812% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -167.12% |
| Histogen Inc. | 5.69 Million USD | -2194.313% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -2880.364% |
| Surrozen, Inc. | 8.14 Million USD | -1504.751% |
| Organovo Holdings, Inc. | 2.74 Million USD | -4656.441% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -41545.266% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -132.451% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -691.588% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -155.772% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -15707.347% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -3.142% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -1108.729% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | 13.375% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -4913.03% |
| Apollomics, Inc. | 14.15 Million USD | -823.529% |
| Amarin Corporation plc | 279.58 Million USD | 53.25% |
| Mesoblast Limited | 188.79 Million USD | 30.769% |
| Turnstone Biologics Corp. | 14.14 Million USD | -823.855% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | 27.702% |
| Synaptogenix, Inc. | 5.52 Million USD | -2263.826% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -1866.11% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | 23.162% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -1427.452% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -7337.551% |
| Exelixis, Inc. | 678.44 Million USD | 80.734% |
| Better Therapeutics, Inc. | 23.84 Million USD | -448.222% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | 20.323% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 78.003% |
| NLS Pharmaceutics AG | 10.68 Million USD | -1123.825% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -7950.364% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -235.775% |
| Gritstone bio, Inc. | 125.91 Million USD | -3.802% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -790.617% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -2468.61% |
| Avid Bioservices, Inc. | 275.66 Million USD | 52.585% |
| Insmed Incorporated | 1.66 Billion USD | 92.134% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -1598.812% |
| MediWound Ltd. | 27.18 Million USD | -380.77% |
| OmniAb, Inc. | 87.4 Million USD | -49.55% |
| Alector, Inc. | 487.66 Million USD | 73.198% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 67.603% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -609.4% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -240.622% |
| Zai Lab Limited | 240.17 Million USD | 45.579% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 79.255% |
| Aura Biosciences, Inc. | 29.22 Million USD | -347.213% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -37.475% |
| Immunic, Inc. | 25.36 Million USD | -415.244% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -88.785% |
| Veracyte, Inc. | 93.71 Million USD | -39.467% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -4895.16% |
| FibroGen, Inc. | 585.72 Million USD | 77.685% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -651.924% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -19914.057% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -2211.166% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 98.293% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -1494.377% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -55.563% |
| TG Therapeutics, Inc. | 169.08 Million USD | 22.697% |
| Galecto, Inc. | 5.89 Million USD | -2116.876% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -1477.825% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 95.008% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -353.497% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -935.631% |
| XBiotech Inc. | 8.39 Million USD | -1456.592% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -790.617% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -145.782% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 64.003% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -386.189% |
| Theravance Biopharma, Inc. | 169 Million USD | 22.66% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 89.248% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 73.881% |
| Vaxxinity, Inc. | 30.94 Million USD | -322.399% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 86.56% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -2067.214% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 82.461% |
| NexImmune, Inc. | 5.08 Million USD | -2470.831% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -35093.622% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -4150.844% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 98.161% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -2436.016% |
| Scopus BioPharma Inc. | 7.45 Million USD | -1653.413% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -397.098% |
| Ainos, Inc. | 7.39 Million USD | -1667.691% |
| Pluri Inc. | 34.11 Million USD | -283.17% |
| Prothena Corporation plc | 135.01 Million USD | 3.192% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | 46.234% |
| Celularity Inc. | 102.92 Million USD | -26.988% |
| Rallybio Corporation | 9.43 Million USD | -1285.195% |
| Cue Biopharma, Inc. | 24.44 Million USD | -434.698% |
| MeiraGTx Holdings plc | 319.99 Million USD | 59.153% |
| Omeros Corporation | 403.25 Million USD | 67.587% |
| Humacyte, Inc. | 114.67 Million USD | -13.978% |
| Immunocore Holdings plc | 228.15 Million USD | 42.712% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -2581.169% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -70.324% |
| Blueprint Medicines Corporation | 918.64 Million USD | 85.772% |
| CalciMedica, Inc. | 4.02 Million USD | -3144.96% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -648.951% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | 15.204% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -52.309% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 52.948% |
| Pulmatrix, Inc. | 15.96 Million USD | -718.812% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -728.676% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -431.2% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 47.886% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -157.368% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 89.203% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -311.248% |
| Nutriband Inc. | 1.07 Million USD | -12014.626% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -1129.258% |
| Vor Biopharma Inc. | 59.1 Million USD | -121.147% |
| Roivant Sciences Ltd. | 773.95 Million USD | 83.112% |
| Evogene Ltd. | 17.99 Million USD | -626.554% |
| ProKidney Corp. | 29.21 Million USD | -347.382% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -81.59% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -18440.447% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 93.08% |
| CorMedix Inc. | 11.91 Million USD | -996.763% |
| BioLineRx Ltd. | 50.7 Million USD | -157.795% |
| Tango Therapeutics, Inc. | 149.45 Million USD | 12.547% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -47.79% |
| Atai Life Sciences N.V. | 49.16 Million USD | -165.87% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -319.574% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -627.686% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -4.871% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -2211.762% |
| MediciNova, Inc. | 3.89 Million USD | -3258.736% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -615.066% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -8589.233% |
| GeoVax Labs, Inc. | 3.51 Million USD | -3613.393% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 67.098% |
| Biomea Fusion, Inc. | 30.69 Million USD | -325.894% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 95.198% |
| Mereo BioPharma Group plc | 15.96 Million USD | -718.864% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -318.919% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -122.73% |
| Absci Corporation | 58.3 Million USD | -124.182% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -586.198% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -307.67% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -77.134% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -49.408% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -287.051% |
| Allakos Inc. | 74.79 Million USD | -74.758% |
| Imunon, Inc. | 8.53 Million USD | -1432.245% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -480.894% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -13.844% |
| BioAtla, Inc. | 48.98 Million USD | -166.825% |
| NLS Pharmaceutics AG | 10.68 Million USD | -1123.825% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -4603.383% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -0.079% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -819.501% |
| XOMA Corporation | 145.58 Million USD | 10.216% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -288.258% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -90.094% |
| aTyr Pharma, Inc. | 31.59 Million USD | -313.669% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -111.421% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -190.686% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -170.045% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -4454.251% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -1502.191% |
| Akari Therapeutics, Plc | 4.58 Million USD | -2751.374% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -637.078% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 92.076% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -32260.587% |
| UroGen Pharma Ltd. | 243.52 Million USD | 46.327% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 59.292% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -4633.089% |
| Orgenesis Inc. | 35.53 Million USD | -267.826% |
| Entera Bio Ltd. | 1.37 Million USD | -9378.39% |
| GH Research PLC | 6.7 Million USD | -1850.56% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -1822.162% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -594.29% |
| Xencor, Inc. | 283.55 Million USD | 53.905% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -4277.804% |
| Replimune Group, Inc. | 113.21 Million USD | -15.451% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -3378.91% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -26.25% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -32260.587% |
| Portage Biotech Inc. | 4.45 Million USD | -2837.236% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -8589.233% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -467.059% |
| OncoCyte Corporation | 49.29 Million USD | -165.137% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -3059.612% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -16289.921% |
| Purple Biotech Ltd. | 10 Million USD | -1206.417% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -2159.022% |
| scPharmaceuticals Inc. | 57.26 Million USD | -128.265% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -955.108% |
| HilleVax, Inc. | 78.9 Million USD | -65.643% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -2488.257% |
| Tharimmune, Inc. | 1.81 Million USD | -7101.305% |
| Genprex, Inc. | 3.25 Million USD | -3916.553% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -381.976% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -2396.314% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -63350.0% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -36354.533% |
| OKYO Pharma Limited | 7.42 Million USD | -1661.349% |
| Savara Inc. | 37.19 Million USD | -251.438% |
| Curis, Inc. | 57.61 Million USD | -126.875% |
| Daré Bioscience, Inc. | 26.32 Million USD | -396.421% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -233.438% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -8951.731% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -527.826% |
| BeiGene, Ltd. | 2.23 Billion USD | 94.149% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -513.942% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | 50.187% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -514.398% |
| Erasca, Inc. | 78.61 Million USD | -66.271% |
| bluebird bio, Inc. | 424.62 Million USD | 69.218% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -19847.593% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 93.084% |
| DBV Technologies S.A. | 42.8 Million USD | -205.39% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -19847.593% |
| Moderna, Inc. | 4.57 Billion USD | 97.141% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -1768.578% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -7792.935% |
| Molecular Templates, Inc. | 31.17 Million USD | -319.322% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -665.712% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 77.775% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -4.981% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -376.39% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -258.534% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -134.937% |
| MacroGenics, Inc. | 154.2 Million USD | 15.239% |
| RenovoRx, Inc. | 4.46 Million USD | -2826.713% |
| Adicet Bio, Inc. | 37.12 Million USD | -252.12% |
| Prime Medicine, Inc. | 60.78 Million USD | -115.049% |
| Aditxt, Inc. | 28.53 Million USD | -358.114% |
| Adagene Inc. | 45.16 Million USD | -189.371% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -72233.302% |
| Quantum-Si incorporated | 26.63 Million USD | -390.808% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 81.262% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -4196.127% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -13.697% |
| SciSparc Ltd. | 1.59 Million USD | -8094.796% |
| Vericel Corporation | 127.7 Million USD | -2.351% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -2248.778% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -53.128% |
| Generation Bio Co. | 171.63 Million USD | 23.844% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -1031.662% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -212.464% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | 48.275% |
| Invivyd, Inc. | 51.71 Million USD | -152.755% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -42.108% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -1909.254% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -73.131% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -12701.861% |
| 2seventy bio, Inc. | 310.12 Million USD | 57.854% |
| ADMA Biologics, Inc. | 193.97 Million USD | 32.617% |
| Clene Inc. | 38.95 Million USD | -235.568% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -261.74% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | 49.136% |
| GeoVax Labs, Inc. | 3.51 Million USD | -3613.393% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | 31.302% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -973.158% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | 34.094% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -971.826% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -171.678% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -147.359% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 64.66% |
| Evaxion Biotech A/S | 17.61 Million USD | -641.917% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | 18.78% |
| Verve Therapeutics, Inc. | 153.18 Million USD | 14.674% |
| Trevena, Inc. | 48.26 Million USD | -170.828% |
| Surrozen, Inc. | 8.14 Million USD | -1504.751% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -505.265% |
| Cingulate Inc. | 10.36 Million USD | -1161.545% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -4652.982% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -250.496% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -3544.396% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -893.97% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 58.794% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -426.005% |
| Clearmind Medicine Inc. | 3.61 Million USD | -3520.684% |
| Kronos Bio, Inc. | 54.2 Million USD | -141.152% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -177.846% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -474.291% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -551.223% |
| Statera Biopharma, Inc. | 22.67 Million USD | -476.4% |
| ImmunityBio, Inc. | 1.09 Billion USD | 88.013% |
| Korro Bio, Inc. | 51.75 Million USD | -152.564% |
| Kineta, Inc. | 7.22 Million USD | -1709.845% |
| BioVie Inc. | 9.7 Million USD | -1247.199% |
| Codexis, Inc. | 49.94 Million USD | -161.697% |
| Celularity Inc. | 102.92 Million USD | -26.988% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -35.804% |
| Celcuity Inc. | 51.45 Million USD | -154.046% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -37764.795% |
| Cibus, Inc. | 206.11 Million USD | 36.586% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -207.727% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -396.249% |
| IN8bio, Inc. | 8.77 Million USD | -1390.048% |
| Kodiak Sciences Inc. | 213.59 Million USD | 38.805% |
| Annexon, Inc. | 47.11 Million USD | -177.404% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -45.974% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -35.628% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -854.832% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 94.979% |
| Eyenovia, Inc. | 19.78 Million USD | -560.794% |
| Puma Biotechnology, Inc. | 177.08 Million USD | 26.19% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -1601.692% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -442.375% |
| Arcellx, Inc. | 339.75 Million USD | 61.529% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -998.563% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | 46.768% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -1266.799% |
| Moolec Science SA | 13.94 Million USD | -837.28% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -202.899% |
| Geron Corporation | 146.12 Million USD | 10.552% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -158.662% |
| Royalty Pharma plc | 6.29 Billion USD | 97.924% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -228.608% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -44296.853% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -5212.684% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | 30.9% |
| Humacyte, Inc. | 114.67 Million USD | -13.978% |
| Structure Therapeutics Inc. | 29.05 Million USD | -349.922% |
| 89bio, Inc. | 59.96 Million USD | -117.979% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -393.924% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -10828.679% |
| Genelux Corporation | 8.42 Million USD | -1452.34% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -1806.461% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | 4.117% |
| Notable Labs, Ltd. | 4.42 Million USD | -2852.496% |
| Liquidia Corporation | 73.13 Million USD | -78.713% |
| Mustang Bio, Inc. | 17.61 Million USD | -641.853% |
| Immunovant, Inc. | 48.95 Million USD | -166.994% |
| Quantum-Si incorporated | 26.63 Million USD | -390.808% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -240.534% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -4112.278% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -76.963% |
| Acasti Pharma Inc. | 11.55 Million USD | -1030.977% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -478.152% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -4708.222% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -254.44% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -9490.767% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -2044.144% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -426.302% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -463.781% |
| PepGen Inc. | 34.63 Million USD | -277.428% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -976.309% |
| United Therapeutics Corporation | 1.18 Billion USD | 88.944% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -1771.521% |
| Solid Biosciences Inc. | 38.45 Million USD | -239.869% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -1427.452% |
| Immuneering Corporation | 12 Million USD | -988.467% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -41545.266% |
| Silo Pharma, Inc. | 1.56 Million USD | -8229.159% |
| Belite Bio, Inc | 4.21 Million USD | -3003.942% |
| XOMA Corporation | 145.58 Million USD | 10.216% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -5283.32% |
| Bionomics Limited | 10.15 Million USD | -1186.648% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -508.194% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -470.449% |
| uniQure N.V. | 624.01 Million USD | 79.054% |
| Cassava Sciences, Inc. | 14.19 Million USD | -820.796% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -72233.302% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | 23.197% |
| Forte Biosciences, Inc. | 3.66 Million USD | -3465.385% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -50059.45% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -1837.261% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -1601.692% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -651.924% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -1136.819% |
| Altimmune, Inc. | 16.54 Million USD | -690.2% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 78.84% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -470.449% |
| Compugen Ltd. | 55.77 Million USD | -134.347% |
| Peak Bio, Inc. | 20.75 Million USD | -529.811% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -18.326% |
| Benitec Biopharma Inc. | 4.96 Million USD | -2534.16% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | 17.192% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -73.873% |
| Zura Bio Limited | 21.29 Million USD | -513.878% |
| PolyPid Ltd. | 17.46 Million USD | -648.265% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -16.288% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -73.873% |
| Instil Bio, Inc. | 99.8 Million USD | -30.968% |
| argenx SE | 444.95 Million USD | 70.624% |
| Immunome, Inc. | 28.65 Million USD | -356.093% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -1467.794% |
| Verona Pharma plc | 58.84 Million USD | -122.136% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -803.109% |
| Shattuck Labs, Inc. | 14.85 Million USD | -779.649% |
| CervoMed Inc. | 2.59 Million USD | -4935.429% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -2581.719% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -926.28% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -1140.693% |
| Moolec Science SA | 13.94 Million USD | -837.28% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -5477.417% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -135.104% |
| AnaptysBio, Inc. | 364.28 Million USD | 64.12% |
| Design Therapeutics, Inc. | 11.95 Million USD | -993.234% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -930.487% |
| NeurAxis, Inc. | 1.91 Million USD | -6733.499% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -235.766% |
| Lumos Pharma, Inc. | 13.33 Million USD | -880.327% |
| Achilles Therapeutics plc | 19.08 Million USD | -584.796% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -803.109% |
| 180 Life Sciences Corp. | 5.38 Million USD | -2326.247% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -454.125% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -474.291% |
| Nutriband Inc. | 1.07 Million USD | -12014.626% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -327.175% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -800.744% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 67.427% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -302.51% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -901.656% |
| Palisade Bio, Inc. | 2.73 Million USD | -4672.07% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -2388.235% |
| Beam Therapeutics Inc. | 478.38 Million USD | 72.677% |
| Neurogene Inc. | 36.54 Million USD | -257.621% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 67.155% |
| AEON Biopharma, Inc. | 159.88 Million USD | 18.251% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -174.306% |
| Sesen Bio, Inc. | 30.98 Million USD | -321.853% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -403.474% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -1619.328% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 33.223% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | 31.944% |
| Athira Pharma, Inc. | 30.05 Million USD | -334.864% |
| Vaccinex, Inc. | 5.94 Million USD | -2099.714% |
| HCW Biologics Inc. | 15.05 Million USD | -768.373% |
| XOMA Corporation | 145.58 Million USD | 10.216% |
| Nektar Therapeutics | 267.04 Million USD | 51.054% |
| Arvinas, Inc. | 644.6 Million USD | 79.723% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -637.078% |
| Merus N.V. | 102.15 Million USD | -27.955% |
| Omega Therapeutics, Inc. | 146.35 Million USD | 10.689% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -37.413% |
| Rezolute, Inc. | 11.73 Million USD | -1013.917% |
| Clene Inc. | 38.95 Million USD | -235.568% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -4490.431% |
| BeyondSpring Inc. | 48.26 Million USD | -170.789% |
| Synlogic, Inc. | 32.89 Million USD | -297.346% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -794.457% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -7899.204% |
| Peak Bio, Inc. | 20.75 Million USD | -529.811% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -105.971% |
| Krystal Biotech, Inc. | 39.71 Million USD | -229.121% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 65.297% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -31.273% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -30105.488% |
| MannKind Corporation | 721.36 Million USD | 81.881% |
| Ikena Oncology, Inc. | 22.33 Million USD | -485.212% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -6165.916% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -27.407% |
| Gossamer Bio, Inc. | 249.14 Million USD | 47.538% |
| CohBar, Inc. | 1.03 Million USD | -12545.336% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -1122.818% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -586.198% |
| Legend Biotech Corporation | 589.93 Million USD | 77.844% |
| Mural Oncology plc | 37.92 Million USD | -244.619% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 1.454% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -5594.47% |
| Disc Medicine, Inc. | 22.87 Million USD | -471.397% |
| Champions Oncology, Inc. | 28.03 Million USD | -366.228% |
| REGENXBIO Inc. | 262.22 Million USD | 50.155% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -3790.84% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -942.82% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -873.129% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -516.397% |
| Vaxart, Inc. | 34.02 Million USD | -284.15% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -541.058% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -358.109% |
| Cellectis S.A. | 249.57 Million USD | 47.628% |
| Longeveron Inc. | 5.33 Million USD | -2349.073% |
| Repare Therapeutics Inc. | 41.81 Million USD | -212.554% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 94.566% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -116.517% |
| Revolution Medicines, Inc. | 262.39 Million USD | 50.187% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -6103.465% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -1415.268% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -1007.593% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -830.763% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -5976.569% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 97.462% |
| Denali Therapeutics Inc. | 122.96 Million USD | -6.298% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -2248.778% |
| Veru Inc. | 32.81 Million USD | -298.343% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -1802.853% |
| Cingulate Inc. | 10.36 Million USD | -1161.545% |
| Passage Bio, Inc. | 39.26 Million USD | -232.91% |
| Context Therapeutics Inc. | 4.19 Million USD | -3018.222% |
| Exicure, Inc. | 8.54 Million USD | -1428.916% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -342.954% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -1146.491% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -493.018% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | 19.805% |
| Nuvalent, Inc. | 31.82 Million USD | -310.731% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -1954.616% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -107.399% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -626.15% |
| OmniAb, Inc. | 87.4 Million USD | -49.55% |
| Anew Medical, Inc. | 8.24 Million USD | -1485.904% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -241.369% |
| Lipocine Inc. | 2.63 Million USD | -4866.772% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -397.514% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -225.045% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -390.609% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -51.713% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -2320.052% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -57.96% |
| Ocugen, Inc. | 23.98 Million USD | -444.999% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -181.654% |
| Q32 Bio Inc. | 233.12 Million USD | 43.933% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -1341.727% |
| Alumis Inc. Common Stock | 53.5 Million USD | -144.303% |
| Equillium, Inc. | 27.95 Million USD | -367.529% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | 36.732% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -2222.992% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -2031.219% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 16.92% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -88.249% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -1210.451% |
| Dominari Holdings Inc. | 4.63 Million USD | -2720.0% |
| Edesa Biotech, Inc. | 1.84 Million USD | -6997.327% |
| vTv Therapeutics Inc. | 29.56 Million USD | -342.071% |
| Bio-Techne Corporation | 744.34 Million USD | 82.44% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -3.654% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 62.054% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -222.137% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -351.383% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -41.519% |
| Nkarta, Inc. | 105.6 Million USD | -23.776% |
| BioCardia, Inc. | 4.59 Million USD | -2747.647% |
| Iterum Therapeutics plc | 32.66 Million USD | -300.181% |